CVS Health (NYSE:CVS) Stock Gets Price Target Trim from Leerink Partners

CVS Health (NYSE:CVS) had its price target cut by Leerink Partners from $119.00 to $112.00 in a research report sent to investors on Monday morning, MarketBeat.com reports. They currently have an outperform rating on the pharmacy operator’s stock.

A number of other analysts have also recently weighed in on CVS. Argus boosted their price target on CVS Health from $104.00 to $114.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. HSBC reissued a “hold” rating and issued a $103.00 price objective on shares of CVS Health in a research note on Monday, July 6th. Cantor Fitzgerald reissued a “neutral” rating on shares of CVS Health in a research note on Friday, October 9th. UBS Group restated a “buy” rating on shares of CVS Health in a report on Tuesday, September 22nd. Finally, Bank of America upped their target price on CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Twenty analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.80.

CVS Health Stock Up 3.3%

CVS Health stock opened at $90.42 on Monday. The company has a market capitalization of $115.64 billion, a P/E ratio of 11.17, a P/E/G ratio of 0.82 and a beta of 0.60. The firm’s fifty day simple moving average is $91.88 and its 200-day simple moving average is $92.87. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. CVS Health has a 1-year low of $69.51 and a 1-year high of $110.68.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. The business had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts forecast that CVS Health will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be paid a dividend of $0.6650 per share. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health’s payout ratio is currently 70.37%.

Hedge Funds Weigh In On CVS Health

A number of hedge funds have recently made changes to their positions in CVS. Mather Group LLC. increased its position in CVS Health by 41.2% during the third quarter. Mather Group LLC. now owns 14,807 shares of the pharmacy operator’s stock worth $1,269,000 after buying an additional 4,319 shares during the last quarter. Cliftonlarsonallen Wealth Advisors LLC raised its stake in CVS Health by 9.5% in the third quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 12,130 shares of the pharmacy operator’s stock valued at $1,039,000 after buying an additional 1,053 shares during the period. Fortitude Family Office LLC raised its stake in CVS Health by 110.6% in the third quarter. Fortitude Family Office LLC now owns 990 shares of the pharmacy operator’s stock valued at $85,000 after buying an additional 520 shares during the period. Western Financial Corp CA acquired a new stake in shares of CVS Health in the third quarter valued at approximately $4,509,000. Finally, Sanders Morris Harris LLC acquired a new stake in shares of CVS Health in the third quarter valued at approximately $576,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Aetna reported strong 2027 Medicare Advantage ratings. More than 69% of Aetna’s Medicare Advantage members are enrolled in plans rated four stars or higher by CMS for 2027, supporting the business’s quality reputation and potentially helping preserve bonus payments and member retention. Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
• Positive Sentiment: Analysts see CVS as favorably positioned within Medicare Advantage. A comparison with Alignment Healthcare highlighted CVS’s stronger recent returns, rising earnings estimates and lower valuation, with Aetna’s turnaround cited as a potential catalyst. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
• Positive Sentiment: CVS is expanding pharmacy access. The company opened its first pharmacy-focused location in the Boston area, designed to improve access to medications, immunizations and other pharmacy services in underserved communities. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Neutral Sentiment: MinuteClinic received its seventh consecutive Joint Commission accreditation. The recognition, including evaluation under medical-center standards, reinforces CVS’s healthcare-services credentials; approximately 80% of surveyed locations offer primary care. MinuteClinic earns seventh consecutive Joint Commission accreditation
• Negative Sentiment: CVS agreed to pay $315 million to resolve a Justice Department opioid case. The government alleged that CVS pharmacies improperly filled medically unnecessary or invalid controlled-substance prescriptions from 2013 through 2025 and submitted false claims to federal programs. CVS admitted no wrongdoing and disagreed with the allegations, but the settlement creates a substantial cash cost and includes enhanced monitoring and controlled-substance oversight obligations. CVS Agrees to Pay $315M for Opioid Prescription Allegations

CVS Health Company Profile

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.